227 related articles for article (PubMed ID: 8762100)
21. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; Dunwiddie CT; Perrone MH
Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):908-14. PubMed ID: 9633930
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
[TBL] [Abstract][Full Text] [Related]
23. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
[TBL] [Abstract][Full Text] [Related]
25. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
[TBL] [Abstract][Full Text] [Related]
27. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
[TBL] [Abstract][Full Text] [Related]
28. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
Escolar G; Bozzo J; Maragall S
Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule direct antithrombins: argatroban.
Fareed J; Jeske WP
Best Pract Res Clin Haematol; 2004 Mar; 17(1):127-38. PubMed ID: 15171962
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
31. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M
Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132
[TBL] [Abstract][Full Text] [Related]
32. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Imura Y; Stassen JM; Collen D
J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394
[TBL] [Abstract][Full Text] [Related]
33. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
34. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin.
Sudo Y; Lucchesi BR
J Cardiovasc Pharmacol; 1996 Apr; 27(4):545-55. PubMed ID: 8847872
[TBL] [Abstract][Full Text] [Related]
35. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Matsuo T; Koide M; Kario K
Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
Cadroy Y; Caranobe C; Bernat A; Maffrand JP; Sié P; Boneu B
Thromb Haemost; 1987 Aug; 58(2):764-7. PubMed ID: 3672429
[TBL] [Abstract][Full Text] [Related]
37. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Carteaux JP; Gast A; Tschopp TB; Roux S
Circulation; 1995 Mar; 91(5):1568-74. PubMed ID: 7867200
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
39. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
